Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease

Annals of Medicine

Volumn 32, Issue SUPPL. 1, 2000, Pages 53-59

  Husted, S ^a   Kher, A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antithrombotic therapy; Low molecular weight heparin; Non ST segment elevation myocardial infarction; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ANTICOAGULATION; BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; TITRIMETRY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; DALTEPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SYNDROME;

EID: 0034511440     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
2. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
3. Aspirin, sulfinpyrazone, or both in unstable angina
4. Aspirin, heparin, or both to treat unstable angina
5. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
6. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial
7. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
8. Low-molecular-weight heparin. A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina
9. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
10. FRISC (Fragmin during instability in coronary artery disease study group) low molecular weight heparin during instability in coronary artery disease
11. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study
12. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
13. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: F.R.A.X.I.S
14. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
15. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
16. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
17. Non-Q-acute myocardial interaction: Clinical approach to diagnosis and management
18. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial
19. Reactivation of unstable angina after the discontinuation of heparin
20. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 120 patients. A double-blind, randomized, dose-finding study
21. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction